Business Wire

BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research

13.1.2026 12:00:00 CET | Business Wire | Press Release

Share

BlueMatrix, the global leader in capital markets content publishing technology, backed by Thoma Bravo, today announced a partnership with Perplexity to bring AI-enabled research and discovery to institutional investors using BlueMatrix’s governed, entitlement-aware framework.

The partnership brings entitled broker research to Perplexity Enterprise users, enabling buy-side professionals to query their subscribed research content, alongside Perplexity’s broader capabilities, including real-time financial data, earnings transcripts, and deep research tools. Investment professionals and researchers can use natural language to surface relevant insights without changing existing data ownership, entitlements, or compliance structures.

As buy-side teams increasingly turn to AI tools for research synthesis, a formal integration through BlueMatrix replaces unstructured, ungoverned usage with compliant distribution that preserves attribution and entitlements. For research firms, the partnership provides a new channel to increase visibility with buy-side clients, gaining presence within an AI-powered discovery experience while maintaining full control over their content. Research providers also gain new insight into how investors interact with their analysis, the types of questions they’re asking most, and how they’re integrating those results into their AI-assisted workflows.

BlueMatrix provisions access on behalf of research providers, ensuring that only clients with existing agreements can surface a firm’s content. Proprietary research remains fully protected and is never used to train AI models or leave institutional boundaries.

“At BlueMatrix, our priority is to help clients benefit from AI while preserving attributions, control, and flexibility,” said Patricia Horotan, CEO of BlueMatrix. “This new partnership with Perplexity delivers AI-assisted discovery to investors and researchers, alongside Perplexity’s suite of accuracy-driven research tools. For research providers, it offers a new way to ensure that their insights reach clients at the moment of decision, without compromising the governance and data-first, model-neutral strategy they expect from BlueMatrix.”

“BlueMatrix is a clear leader in capital markets technology, and we’re excited to align AI innovation with the strict governance standards financial institutions and researchers require,” said Dmitry Shevelenko, Chief Business Officer at Perplexity. “This partnership demonstrates how AI-powered search can enhance access to entitled research content, and help investment professionals move from question to insight and insight to decisions faster.”

During the initial pilot phase of the partnership, a limited group of early-adopter firms will explore AI-assisted workflows that allow buy-side professionals to ask natural-language questions, such as “What are my brokers saying about this issuer following earnings?”, and receive cited responses grounded in the entitled research they already receive via BlueMatrix and Perplexity’s broader suite of Enterprise data sources.

Use cases will include issuer monitoring, post-earnings and event follow-up, and thematic research. BlueMatrix serves as the secure system of record for research authoring, compliance, and entitlements, while Perplexity Enterprise provides the AI-powered interface for deep research. A private beta will follow integration and security reviews, with feedback from participating firms shaping future features, including expanded entitlement scenarios, deeper use of metadata such as RIXML, and enhanced engagement reporting.

About BlueMatrix

BlueMatrix is the global leader in capital markets content publishing technology, trusted by over 1,000 financial institutions. Its secure platform streamlines authoring, compliance, and distribution—driving smarter, faster collaboration across capital markets. Founded in 1999 and backed by Thoma Bravo, BlueMatrix operates from offices in Durham (HQ), New York, London, Paris, Edinburgh, Auckland, and Timisoara.

www.bluematrix.com

About Perplexity

Perplexity is an AI-powered answer engine that draws from credible sources in real time to accurately answer questions with in-line citations, perform deep research, and more. Perplexity Enterprise provides secure, organization-aware access to AI-assisted research workflows that integrate proprietary data with trusted public sources. Founded in 2022, the company's mission is to serve the world's curiosity by bridging the gap between traditional search engines and AI-driven interfaces. Each week, Perplexity answers more than 150 million questions globally. Perplexity is available in the app store and online at:

www.perplexity.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20260113633321/en/

Contacts

Media Inquiries:
Emily O’Brien
emily@getepic.io

BlueMatrix/Perplexity Inquiries:
https://www.bluematrix.com/www3/RequestInformation.action -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bluematrix
.com%2Fwww3%2FRequestInformation.action&esheet=54395104&newsitemid=2026011363332
1&lan=en-US&anchor=https%3A%2F%2Fwww.bluematrix.com%2Fwww3%2FRequestInformation.
action&index=3&md5=a302ac3671efdca847406350dbf660e9sales@bluematrix.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release

SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press Release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press Release

Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10 At a time whenpatients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Re

Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press Release

Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoint, demonstrating non-inferiority

Tigo Energy Improves Installer Choice via Fronius Compatibility with TS4 Product Line22.10.2026 18:02:00 CEST | Press Release

Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a manufacturer declaration of compatibility from Fronius International GmbH, documenting compatibility between Tigo Flex MLPE products and multiple Fronius inverter families. The letter covers Tigo TS4-A-F, TS4-A-2F, TS4-A-O, and TS4-X-O products and the Fronius Primo GEN24, Primo GEN24 208-240, Symo GEN24, Verto, Tauro, and Tauro ECO inverter families, when configured according to the requirements specified by Fronius and Tigo. Building on established compatibility in Europe, the declaration extends manufacturer-confirmed compatibility to markets worldwide, including the United States and Canada, giving solar professionals greater flexibility to design high-quality systems using manufacturer-confirmed technology combinations. Fronius develops solar technologies and solutions for residential, commercial, and large-scale applications, with a port

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye